Titlebook: Gastrointestinal Stromal Tumors; Bench to Bedside Charles R. Scoggins,Chandrajit P. Raut,John T. Mul Book 2017 Springer International Publi

良心

Neoadjuvant Therapy and Surgical Consolidation for Localized Gastrointestinal Stromal Tumorssease that is locally advanced and either borderline resectable or unresectable. KIT inhibition by the oral drug imatinib is highly effective in most GISTs and can result in a measurable tumor shrinkage in a significant proportion of patients. Neoadjuvant therapy with imatinib has many potential adv

FAST

Prognostic Factors for Advanced GISTematologic malignancies. The recognition of GIST as a separate entity from intestinal leiomyosarcomas laid the foundation for treatment of patients with advanced disease. GISTs are mesenchymal tumors of the intestinal tract originating from specialized nerve cells known as the interstitial cells of

輕信

chassis

LINE

Management of Liver Metastases of Gastrointestinal Stromal Tumorsaggressively when possible. Combinations of tyrosine kinase inhibitors (TKIs) and aggressive surgical resection are current mainstays of therapy. Appropriate patient selection based on presentation and TKI response guides therapy. Salvage therapy may be possible for patients with GIST patients with

冷淡周邊

議程

凈禮

Epidemiology of GIST,fic Islanders. The average age at diagnosis ranges from 62 to 75, with peak incidence in the 8th decade of life. In regard to tumor-related characteristics, the stomach is consistently the most common tumor location followed by the small intestine. Finally, risk factors associated with death include

lesion

竊喜